Press "Enter" to skip to content

EMA approved the use of Pfizer / BioNTech vaccine between the ages of 12-15

last minute “data-mce-href =” “> Breaking news!

In the statement made by the European Medicines Agency (EMA), it was stated that the effect of the vaccine, which can be applied to 16-year-olds and older, is currently being investigated in 2 thousand 260 people in the 12-15 age group.

As a result of the research, it was concluded that the vaccine was effective in children in this age group and provided protection against the disease. According to the statement, Kovid-19 disease was not seen in 1005 children who were given the vaccine, 16 of the 978 children who were given the placebo vaccine got the disease.

EMA’s director of vaccination strategy, Marco Caveleri, said at the press conference that the effect of the vaccine on children is the same as, or even more positive, in young adults.

Stating that the vaccine should be administered to children in 2 doses and at least 3 weeks apart, as in adults, Caveleri emphasized that the side effects in children are the same as in adults.

Caveleri emphasized that the EMA made a recommendation and that the decision on whether to give the vaccine to children or when it will be administered will be made by EU member states.

The EU had signed agreements with companies to purchase an additional 1.8 billion doses of BioNTech-Pfizer vaccine for 2022-2023. The EU administration stated that vaccination of the 12-15 age group could begin in autumn.

Download the NTV application, be informed about the developments

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *